ACA
GILD icon

Aptus Capital Advisors’s Gilead Sciences GILD Stock Holding History

Aptus Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-900,000
Closed -$53.5M – 689
2022
Q1 		$53.5M Buy
+900,000
New +$57.5M 1.33% 19

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aptus Capital Advisors's GILD Position: Q2 2026 in Review

Aptus Capital Advisors reduced its Gilead Sciences (GILD) stake by 0.6% in Q2 2026, selling an estimated $59.4K and leaving 74,929 shares worth $9.47M. The position accounts for 0.06% of the portfolio, ranked #242.

Aptus Capital Advisors first reported a position in GILD in Q4 2018 and has held it in 24 quarters since. The position peaked at $10.5M in Q1 2026. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Aptus Capital Advisors held 74,929 shares of Gilead Sciences worth $9.47M as of Q2 2026.
  • Aptus Capital Advisors sold 451 Gilead Sciences shares in Q2 2026, an estimated $59.4K.
  • Gilead Sciences made up 0.06% of Aptus Capital Advisors's portfolio in Q2 2026, its #242 holding.
  • Aptus Capital Advisors first reported a position in Gilead Sciences in Q4 2018 and has held it in 24 quarters since.
  • Aptus Capital Advisors's Gilead Sciences position peaked at $10.5M in Q1 2026.
  • 2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.